Metastatic enhertu

Enhertu Receives Approval in China as Groundbreaking HER2-Directed Therapy for HER2-Low Metastatic Breast Cancer Patients

Enhertu Receives Approval in China as Groundbreaking HER2-Directed Therapy for HER2-Low Metastatic Breast Cancer Patients

SG Tylor

Source – AstraZeneca  Enhertu (trastuzumab deruxtecan), a targeted antibody drug conjugate developed by AstraZeneca and Daiichi Sankyo, has received approval ...